Hook and thesis
Telix Pharmaceuticals is at the inflection point many radiopharma bulls have been waiting for - real commercial revenue alongside progress in late-stage programs. The company reported Q2 2026 group revenue of $247M, marked a 7% quarter-on-quarter increase and 21% year-on-year growth, and reiterated FY2026 revenue guidance to exceed $1.0B. Those are not typical early-stage biotech numbers; they read like a commercial-stage growth story.
My trade thesis is straightforward: buy TLX at $11.69 with a clearly defined stop and target. The upside is driven by continued commercial momentum in Precision Medicine, regulatory and clinical progress for TLX591-Tx (the ProstACT program), and operational stability following refinancing. The key caveat is execution - on trial enrollments, US Part 2 initiation, and continued commercial uptake. Execution will determine whether valuation compresses or expands.
What Telix does and why the market should care
Telix operates across three segments - Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS) - focusing on radiopharmaceutical diagnostics and therapeutics for oncology. Precision Medicine is the current cash engine: Q2 Precision Medicine revenue was $202M, up 30% year-on-year. That commercial base finances development work and gives Telix optionality to pursue multiple therapeutic programs, rather than burning through capital the way pure R&D-stage biotechs do.
The market cares because radioligand therapies and PSMA-targeted approaches are reshaping metastatic prostate cancer care. Independent research cited a growing market that was already valued at roughly $11.5B in 2025 across major markets, with long-term growth driven by biomarker-driven combinations. Telix sits in the center of that shift with TLX591-Tx (a lutetium radio antibody-drug conjugate) now in Phase 3 ProstACT and with FDA alignment to move Part 2 into the U.S.
Numbers that matter
- Q2 2026 group revenue: $247M (up 7% QoQ, 21% YoY).
- Precision Medicine revenue in Q2: $202M (up 30% YoY) - the primary commercial driver today.
- FY2026 revenue guidance: management expects to exceed $1.0B.
- Market cap: $3.97B.
- P/E ratio: 114.33; Price/Book: 7.89. These reflect significant growth expectations baked into the stock.
- Shares outstanding: 339.78M; current price: $11.69 with 52-week range of $6.28 - $12.60.
Technical and market context
Technically, the trade looks constructive but not euphoric. The 10-day SMA is $11.93 and the 20-day SMA is $11.21; MACD is in bullish momentum with a small positive histogram and RSI around 54, which suggests room for a measured move higher without immediately being overbought. Short interest has fluctuated, with recent settlement showing roughly 277,664 shares short as of 07/31/2026, and daily short-volume spikes have been visible - these create volatility but also opportunities for squeezes if sentiment turns positive.
Valuation framing
At a market cap of ~$3.97B and expected FY2026 revenue >$1.0B, Telix is trading at roughly 4x expected revenue on a simple, back-of-the-envelope basis. The P/E of ~114 indicates profitability is still growing and that investors are paying for future earnings expansion from therapeutics approvals and higher-margin product mix. Compared to classic commercial-stage peers that trade at 3-8x revenue depending on growth profile, Telix sits on the higher side of the range but benefits from proven commercial revenue and late-stage assets in ProstACT. The valuation is defendable only if execution continues - missed enrollments, regulatory delays, or slower commercial uptake would likely compress multiples quickly.
Catalysts to drive the trade
- Continued quarterly commercial momentum - revenues above guidance or acceleration in Precision Medicine sales.
- Regulatory and clinical milestones for TLX591-Tx: FDA alignment was achieved on the Part 2 protocol and Part 1 data presented positive signals at ASCO (06/01/2026); initiation of U.S. Part 2 enrollment would be a major de-risking step.
- Publication and peer-reviewed support - ProstACT SELECT results were published on 07/21/2026 showing imaging can identify suitable patients; more supportive publications or investigator-led data would reduce clinical risk perception.
- Partnerships and commercial expansion - the strategic collaboration with Regeneron and near-term manufacturing or distribution wins can enhance revenue visibility.
Trade plan (actionable)
| Item | Plan |
|---|---|
| Trade direction | Long |
| Entry price | $11.69 |
| Target price | $14.50 |
| Stop loss | $10.00 |
| Horizon | Mid term (45 trading days) - enough time to react to early enrollment updates, quarterlies, or near-term regulatory/clinical announcements. |
| Risk level | Medium |
Rationale: $14.50 is a ~24% upside from $11.69 and represents a reasonable move if revenue growth remains strong and ProstACT Part 2 shows continued progress. The $10.00 stop limits downside if commercial momentum deteriorates or a clinical/regulatory setback pushes the stock toward the 52-week low of $6.28. The 45-trading-day horizon gives time for meaningful operational updates without tying up capital through longer clinical timelines.
Catalyst timeline to watch
- Quarterly and half-year investor updates - note the H1 2026 results webcast announced on 07/30/2026 that accompanied Q2 numbers.
- Regulatory filings and IND amendment activity tied to Part 2 initiation in the U.S. - watch communications following the FDA alignment announcement on 07/02/2026.
- Clinical readouts from ProstACT and supporting publications - the Part 1 ASCO presentation on 06/01/2026 and the 07/21/2026 ProstACT SELECT publication are precedents for market-moving science-driven releases.
Risks and counterarguments
- Clinical risk - TLX591-Tx is in late-stage testing, but Phase 3 Part 2 enrollment, unexpected safety issues, or weaker-than-expected efficacy would materially hurt the stock.
- Regulatory and execution risk - FDA alignment lowers risk but does not guarantee approval. Delays to U.S. enrollment, IND amendments, or additional requested data could push milestones out.
- Commercial execution versus competition - Precision Medicine is strong today, but competition in PSMA-targeting and radioligand spaces is fierce. Market share loss or slower uptake in key geographies could compress forward multiples.
- Valuation sensitivity - with a P/E around 114 and price/book near 7.9, the stock is priced for growth; any slip in revenue growth or margins could create rapid downside.
- Financing and macro risk - while the convertible bond refinancing is complete, further capital raises under stressed market conditions would dilute shareholders and pressure the share price.
Counterargument: The bullish case is clear on revenue and Phase 3 progress, but the valuation and remaining clinical milestones mean a conservative investor could reasonably argue the upside is already priced in. With a P/E >100, a lot is riding on continued stellar execution; one misstep could be punished disproportionately. That is precisely why a strict stop at $10.00 is essential for this trade.
What would change my mind
I would reduce conviction if one of the following occurs: (1) Q3/Q4 commercial revenues miss guidance or show deceleration versus the Q2 trend, (2) ProstACT Part 2 enrollment stalls or the FDA requests additional data that meaningfully delays U.S. entry, or (3) a major competitor posts convincing superiority data in the same indication that undercuts the addressable market. Conversely, my conviction would increase if Telix posts accelerating revenue beats, announces faster-than-expected Part 2 initiation in the U.S., or secures additional commercial partnerships or reimbursement wins that materially de-risk the revenue path.
Conclusion
Telix is an execution story. The company now brings commercial heft to a pipeline that is proving clinically relevant. Q2 revenue of $247M, Precision Medicine strength, and favorable regulatory interactions with the FDA are tangible positives. This trade is a disciplined, mid-term long: enter at $11.69, target $14.50, stop at $10.00, with a 45-trading-day outlook to allow for meaningful clinical and commercial updates. Protect capital, watch the enrollment and revenue cadence closely, and treat any headline as a signal to reassess rather than an automatic trigger to add size.
Trade setup summary - Long TLX at $11.69, target $14.50, stop $10.00, horizon mid term (45 trading days). Execution will decide the next leg.